UNSPSC 51372012: Levorphanol

This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27618J1N2X, chemically known as 1,3,4,9,10,10a-hexahydro-6-hydroxy-2h-10,4a-(iminoethano)-11-methylphenanthrene but generally known as levorphanol, which bears US NIH Compound Identifier 5359272. European Medicines Agency schedules Levorphanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08490MIG.

UNSPSC 51372012 Levorphanol is a Commodity code that does not match the state and local opportunities posted under it. The recent solicitations tagged to this code—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's direct-to-manufacturer prescription RFI, and MMCAP's generic multi-source pharmaceuticals and OTC products RFP—address broader pharmaceutical distribution, emergency response medications, and cooperative purchasing agreements rather than levorphanol specifically. State and local governments buying under this code appear to be seeking opioid-antagonist medications and general pharmacy benefit management solutions through competitive bidding and cooperative purchasing vehicles, but the available opportunities do not isolate levorphanol as a distinct procurement line item or primary scope driver.

Issuing bodies include county public health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). Geographic activity spans Florida, Texas, and the MMCAP multistate footprint including Minnesota and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone annually with quarterly deliveries to Sanford, Florida; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription relationships; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products through three authorized wholesalers, effective July 1, 2026. The code shows limited recent activity specific to levorphanol itself, suggesting either misclassification in the procurement databases or that this particular opioid receptor antagonist is procured infrequently or under higher-tier pharmaceutical family codes.